We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Thombomodulin Identified as Unique Biomarker for Diagnosing Necrotizing Soft-Tissue Infections

By LabMedica International staff writers
Posted on 26 Jul 2021
Print article
Image: Schematic structure of the thrombomodulin protein (Photo courtesy of Wikimedia Commons)
Image: Schematic structure of the thrombomodulin protein (Photo courtesy of Wikimedia Commons)
Thrombomodulin, a protein present in blood plasma, is a biomarker that may be useful for diagnosing necrotizing soft-tissue infections.

Necrotizing soft tissue infections (NSTI) are bacterial infections characterized by rapid tissue degradation. NSTIs are rapidly progressing infections frequently complicated by septic shock and associated with high mortality. Early diagnosis is critical for patient outcome, but challenging due to vague initial symptoms.

Investigators at Karolinska Institutet (Stockholm, Sweden) searched for useful biomarkers to aid in the diagnosis of NSTIs. For the search, the investigators used Luminex (Austin, TX, USA) multiplex assays to analyze 36 soluble factors in blood plasma from the 311 NSTI patients included in the international INFECT study. Control groups included patients with suspected NSTI and sepsis, respectively.

Results of the study pointed to thrombomodulin as being a unique biomarker for detection of NSTI. Thrombomodulin is an integral membrane protein expressed on the surface of endothelial cells and serves as a cofactor for thrombin. It reduces blood coagulation by converting thrombin to an anticoagulant enzyme from a procoagulant enzyme. In humans, thrombomodulin is encoded by the THBD gene. The protein has a molecular mass of 74 kiloDaltons, and consists of a single chain with six tandemly repeated EGF-like domains, a serine/threonine-rich spacer, and a transmembrane domain.

Senior author Dr. Anna Norrby-Teglund, professor of medicine at Karolinska Institutet, said, "The new biomarker, thrombomodulin, proved to be superior to the laboratory parameters used clinically today. There are currently no tools for safe, rapid diagnosis in life-threatening soft tissue infections. Our findings are consequently very interesting as the biomarkers identified are possible candidates for improved diagnostics. The results are also relevant for individualized treatment in the future."

The study was published in the July 15, 2021, online edition of the Journal of Clinical Investigation.

Related Links:
Karolinska Institutet

Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
Clinical Chemistry Analyzer
Mispa CXL Pro
Silver Supplier
Automated Body Fluid Cell Count Control
Cell-Chex Auto
Automated RNA Extraction & PCR Setup
Omnia LH 75 Pro

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.